Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Contact us
- Phone/fax: +7 495 442 37 85
- Phone: +7 985 908 58 18
- E-mail: info@regdrug.com
- pharegis.com | regdrug.com
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
PSRN: 1157746918933
TAX ID (TIN): 7718278100
D-U-N-S: 362071645
-
- +7 495 442 37 85 9am-6pm GMT+3
-
- + 7 495 442 37 85
-
- + 7 985 908 58 18
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
- FDA Approves Numbrino (cocaine hydrochloride) Nasal Solution for Nasal Anesthesia
- FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment
- FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
- FDA Approves Expanded Indication of Mycamine (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
News and press releases
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2020, PRAC, 17/01/2020
- EMA suspends Picato as a precaution while review of skin cancer risk continues, PRAC, 17/01/2020
- PRAC confirms four-week limit for use of high-strength estradiol creams, PRAC, 17/01/2020
- EMA welcomes new Head of Information Management Division , , 16/01/2020
Drugs.com - Clinical Trials
- Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy MIAMI, Jan. 13,...
- Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease TARRYTOWN, N.Y., Jan. 9,...
- Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer CAMBRIDGE, Mass., Jan....
- PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma SAN FRANCISCO –...